Pancreatic cancer (PC) is the most aggressive malignant disease, ranks as the fourth most leading cause of
cancer-related death among men and women in the United States. We present here that
plumbagin (PL), a quinoid constituent isolated from the roots of the medicinal plant Plumbago zeylanica L, inhibits the growth of PC cells both in vitro and in vivo model systems. PL treatment induces apoptosis and inhibits cell viability of PC cells (PANC1, BxPC3 and ASPC1). In addition, i.p. administration of PL (2 mg/kg
body weight, 5 days a week) in
severe combined immunodeficiency (SCID) mice beginning 3 days after ectopic implantation of PANC1 cells resulted in a significant (P < 0.01) inhibition of both
tumor weight and volume. PL treatment inhibited (1) constitutive expression of
epidermal growth factor receptor (EGFR), pStat3Tyr705 and pStat3Ser727, (2)
DNA binding of Stat3 and (3) physical interaction of EGFR with Stat3, in both cultured PANC1 cells and their xenograft
tumors. PL treatment also inhibited phosphorylation and
DNA-binding activity of NF-κB in both cultured PC cells (PANC1 and ASPC1) and in PANC1 cells xenograft
tumors. Downstream target genes (cyclin D1, MMP9 and
Survivin) of Stat3 and NF-κB were similarly inhibited. These results suggest that PL may be used as a novel therapeutic agent against human PC. Published 2012 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America.